This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Dewilde S, et al. Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective. Cost Effectiveness and Resource Allocation : No. 18, 10 Feb 2020. Available from: URL: https://doi.org/10.1186/s12962-020-0205-4
About this article
Cite this article
Dexrazoxane cost effective in preventing anthracycline cardiotoxicity. Reactions Weekly 1791, 8 (2020). https://doi.org/10.1007/s40278-020-74853-5